Please assess the completion status of the following clinical trial:

Trial Title: Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-79 years~* Stable does of statins ≥ 8 weeks prior to screening~* Good health by medical history, physical exam, electrocardiogram, laboratory test (e.g., serum chem., urinalysis)~* Mean fasting serum triglyceride of two most recent tests in medical record ≥ 200 and \< 500 mg/dL~* Mean LDL-cholesterol of two most recent tests in medical record ≤ 1.1 × NCEP ATP III goal~Exclusion Criteria:~* Medications, vitamin pills, nutritional supplements or herbal preparations deemed exclusionary per primary investigator for possible interference~* Poorly controlled diabetes mellitus (e.g. \[HbA1c\] \> 8.0%)~* History of a cardiovascular event~* Past revascularization procedure~* Past aortic aneurysm or an aortic dissection \< 6 months prior to screening~* History of pancreatitis~* Sensitivity to any statin OR to omega-3 fatty acids or fish products~* Poorly controlled hypertension (i.e.: \>=160 systolic (resting) and/or \>=100 diastolic (resting)) at 2 consecutive visits~* Serum Creatinine ≥ 2.0 mg/dL~* Serum transaminase \> 1.5 × upper limit of normal (ULN); including aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\]; 31 U/L for AST, 45 U/L for ALT~* Creatine Kinase (CK) \> 3.0 × ULN~* Taking other triglyceride lowering drugs (e.g., niacin, fibrates) or fish oil supplements providing more than 500 mg of EPA+DHA per day~* Contraindications for Lovaza per product insert~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Lovaza (Type: EXPERIMENTAL): Lovaza was given as the only agent; there was no comparator agent or arm

Based on this trial design, predict the completion outcome and termination type (if applicable).